CORE LAB REPORTS THIRD QUARTER 2026 RESULTS:
Core Laboratories reported Q3 2026 revenue of $132.1 million, up 6% sequentially but down 2% year-over-year, with GAAP EPS of $0.12 and EPS ex-items of $0.16. Sequential momentum was driven by international laboratory demand and a 14% rise in Production Enhancement product sales, though Middle East conflict and Russia-Ukraine sanctions continued to weigh on results. Free cash flow was just $1.7 million due to working capital build. For Q4 2026 the company guided revenue of $128.5M-$134.5M (roughly flat sequentially) with EPS of $0.12-$0.20, citing project delays from attacks on client operations in the Middle East.
Key figures
- Eps
- 0.12
- Revenue
- 132077000
- Guidance
- Q4 2026 revenue $128.5M-$134.5M; operating income $10.7M-$15.1M (~10% margins); EPS $0.12-$0.20; revenue relatively flat sequentially
- Revenue Yoy
- -1.8%
- Fcf
- 1723000
- Roic
- 5.9%
- Net debt
- 93400000
- Eps ex items
- 0.16
- Buyback amount
- $1.1 million
- Buyback shares
- 87873
- Operating income
- 12065000
- Quarterly dividend
- $0.01 per share
- Operating income ex items
- 12613000
- Segment revenue reservoir description
- 84318000
- Segment revenue production enhancement
- 47759000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.